FBT — First Trust NYSE Arca Biotechnology Index Fund
Data updated: 2026-08-21
FBT — First Trust NYSE Arca Biotechnology Index Fund. United States Mid Cap Blend / Core Health Care Equity. Holdings, fees, performance and SEC filings.
FBT Fund Overview
FBT — First Trust NYSE Arca Biotechnology Index Fund is a US ETF managed by First Trust Exchange-Traded Fund, categorised as United States Mid Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: First Trust Exchange-Traded Fund
- Category: United States Mid Cap Blend / Core Health Care Equity
- Assets under management: $2.81B
- 1-year return: 53.9%
- Ticker: FBT
- SEC CIK: 0001329377
- SEC series ID: S000012478
- Share class ID: C000033929
FBT Holdings
Top 10 holdings of First Trust NYSE Arca Biotechnology Index Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Corcept Therapeutics, Inc. | 5.60% |
| Neogenomics, Inc. | 5.12% |
| Veracyte, Inc. | 5.10% |
| Bruker Corp. | 4.32% |
| Alkermes PLC | 4.24% |
| Illumina, Inc. | 3.92% |
| Krystal Biotech, Inc. | 3.87% |
| Natera, Inc. | 3.79% |
| Axsome Therapeutics, Inc. | 3.71% |
| Neurocrine Biosciences, Inc. | 3.53% |
FBT Portfolio Allocation
Asset-class allocation of First Trust NYSE Arca Biotechnology Index Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 100.0% |
| Cash & Equivalents | 0.1% |
FBT Performance
Total returns for FBT (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 20.4% |
| 1 year | 53.9% |
| 3 years (annualised) | 17.8% |
| 5 years (annualised) | 7.6% |
FBT Risk Information
Risk metrics for FBT, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 18.3%
FBT Costs and Fees
FBT costs about $55 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.55%
- Gross expense ratio: 0.55%
- Portfolio turnover: 37%
- Brokerage commissions: 1.20 bps of average net assets (SEC N-CEN)
FBT Cashflows
Over the 12 months to 2026-06, First Trust NYSE Arca Biotechnology Index Fund had net inflows of $1.11B, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | −$49.80M |
| 2026-05 | $62.55M |
| 2026-04 | −$10.24M |
| 2026-03 | −$18.52M |
| 2026-02 | $21.04M |
| 2026-01 | $1.06B |
FBT Debt Constituents
No individual debt constituents are reported in First Trust NYSE Arca Biotechnology Index Fund's latest SEC N-PORT filing.
FBT Prospectus and SEC Filings
Official First Trust NYSE Arca Biotechnology Index Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2026-04-30
- Prospectus (485BPOS) — filed 2025-04-30
- Prospectus (485BPOS) — filed 2024-04-29
- Portfolio holdings (N-PORT) — filed 2026-08-21
- Portfolio holdings (N-PORT) — filed 2026-05-28
- Portfolio holdings (N-PORT) — filed 2026-02-23
- Annual census (N-CEN) — filed 2026-03-13
- Annual census (N-CEN) — filed 2025-03-11
Related Funds
Other United States Mid Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.